AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.

doi:10.1126/scitranslmed.ado2817

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.

Science translational medicine - 26 Jun 2024

Cai Yingyun, Diallo Seme, Rosenthal Kim, Ren Kuishu, Flores Daniel J, Dippel Andrew, Oganesyan Vaheh, van Dyk Nydia, Chen Xiaoru, Cantu Erin, Choudhary Rakesh, Sulikowski Michal, Adissu Hibret, Chawla Bhavna, Kar Swagata, Liu Chang, Dijokaite-Guraliuc Aiste, Mongkolsapaya Juthathip, Rajan Saravanan, Loo Yueh-Ming, Beavon Rohini, Webber Chris, Chang Lee-Jah, Thomas Steven, Clegg Lindsay, Zhang Huixia, Screaton Gavin R, Philbin Nora, Harre Mark, Selim Abdulhafez, Martinez-Alier Nuria, Uriel Alison, Cohen Taylor S, Perez John L, Esser Mark T, Blair Wade, Francica Joseph R

Abstract excerpt

The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in variants that can escape neutralization by therapeutic antibodies. Here, we describe AZD3152, a SARS-CoV-2-neutralizing monoclonal antibody designed to provide improved potency and coverage against emerging variants. AZD3152 binds to the back left shoulder of the SARS-CoV-2 spike protein receptor binding domain and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Antibodies, Neutralizing

Share to Antibodies, Viral

Share to COVID-19 Drug Treatment

Share to Mesocricetus

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed

Identifiers

PMID: 38924429
DOI: 10.1126/scitranslmed.ado2817

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults.PMID 38924429Read ↗

AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humansSemantic proximity Read ↗

The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamstersSemantic proximity Read ↗

Structure-based phylogeny identifies avoralstat as a TMPRSS2 inhibitor that prevents SARS-CoV-2 infection in miceSemantic proximity Read ↗

Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infectionSemantic proximity Read ↗

Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail.Semantic proximity Read ↗

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodiesSemantic proximity Read ↗

Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escapeSemantic proximity Read ↗

Broad sarbecovirus neutralization by a human monoclonal antibody.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.